Receiving perioperative Opdivo for non-small cell lung cancer showed event-free survival benefits compared with placebo. Patients with resectable (surgically unremovable) non-small cell lung cancer ...
PRINCETON, N.J.--(BUSINESS WIRE)-- Bristol Myers Squibb (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) has accepted the supplemental Biologics License Application (sBLA) ...
(Reuters) -Bristol Myers Squibb Co said on Tuesday its blockbuster cancer immunotherapy, Opdivo, in combination with chemotherapy improved survival in patients with a type of bladder cancer in a ...
Treatment with neoadjuvant Opdivo, followed by Opdivo after surgery led to significantly improved event-free survival in the first phase 3 perioperative study in patients with resectable non-small ...
If approved, the Opdivo-based regimen would be the first immunotherapy-chemotherapy combination approved for the first-line treatment of untreated, unresectable or metastatic urothelial carcinoma in ...
FILE PHOTO: Test tubes are seen in front of a displayed Bristol Myers Squibb logo in this illustration (Reuters) - Bristol Myers Squibb said on Thursday the injectable form of its blockbuster cancer ...
Based on the Phase 3 CheckMate-8HW trial, Opdivo plus Yervoy demonstrated reduction in the risk of disease progression or death by 79% vs. chemotherapy in the first-line setting and by 38% vs. Opdivo ...
Based on the Phase 3 CheckMate-9DW trial, Opdivo plus Yervoy demonstrated a statistically significant overall survival benefit compared to investigator’s choice of lenvatinib or sorafenib 1 In the ...
The U.S. Food and Drug Administration (FDA) on Tuesday approved Bristol Myers Squibb & Co’s (NYSE:BMY) Opdivo (nivolumab) plus Yervoy (ipilimumab) as a first-line treatment of adult and pediatric ...
Zacks Investment Research on MSN
Here's Why Replimune Stock Skyrockets Nearly 131% in 3 Months
Shares of Replimune Group REPL have surged 131.1% over the past three months, fueled by positive regulatory updates. In ...
On Friday, the European Commission (EC) approved Bristol Myers Squibb & Co’s (NYSE:BMY) Opdivo (nivolumab) plus Yervoy (ipilimumab) for the first-line treatment of adult patients with unresectable or ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback